Plasmapheresis in immunologic renal disease

Blood Purification

Volumn 33, Issue 1-3, 2012, Pages 190-198

  Pusey, Charles D ^a   Levy, Jeremy B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Autoantibodies; Glomerulonephritis; Immune complexes; Plasmapheresis; Renal disease; Renal transplantation; Therapeutic plasma exchange

Indexed keywords

AUTOANTIBODY; BASEMENT MEMBRANE ANTIBODY; BLOOD CLOTTING FACTOR; COMPLEMENT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HEPARIN; HLA ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PREDNISOLONE;

ANCA ASSOCIATED VASCULITIS; ANTIGEN ANTIBODY COMPLEX; BLOOD GROUP ABO INCOMPATIBILITY; CONFERENCE PAPER; CRYOGLOBULINEMIA; DESENSITIZATION; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNOPATHOLOGY; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; MULTIPLE MYELOMA; PLASMAPHERESIS; PRIORITY JOURNAL; SMALL VESSEL VASCULITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT INDICATION;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; EQUIPMENT DESIGN; HUMANS; IMMUNE SYSTEM DISEASES; KIDNEY DISEASES; PLASMAPHERESIS;

EID: 84856063227     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000334155     Document Type: Conference Paper

References (42)

1. Lockwood CM, Boulton-Jones JM, Lowen-thal RM, Simpson IJ, Peters DK: Recovery from Goodpasture's syndrome after immu-nosuppressive treatment and plasmaphere-sis. Br Med J 1975; 2:252-254.
2. Baweja S, Wiggins K, Lee D, Blair S, Fraenkel M, McMahon LP: Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach. J Artif Organs 2011; 14: 9-22.
3. Szczepiorkowski ZM, Bandarenko N, Kim HC, et al: Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007; 22:106-175.
4. Shaz BH, Linenberger ML, Bandarenko N, et al: Category IV indications for therapeutic apheresis: ASFA fourth special issue. J Clin Apher 2007; 22:176-180.
5. Derksen RH, Schuurman HJ, Meyling FH, Struyvenberg A, Kater L: The efficacy of plasma exchange in the removal of plasma components. J Lab Clin Med 1984; 104: 346-354.
6. Jayne DR, Gaskin G, Rasmussen N, et al: Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunc-tive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: 2180-2188.
7. Levy J, Pusey CD: Plasma exchange; in Johnson RJ, Floege J, Feehally J (eds): Comprehensive Clinical Nephrology, ed 3. London, Harcourt Publishers, 2007, pp 1013-1020.
8. Reutter JC, Sanders KF, Brecher ME, Jones HG, Bandarenko N: Incidence of allergic reactions with fresh frozen plasma or cryo-su-pernatant plasma in the treatment of throm-botic thrombocytopenic purpura. J Clin Apher 2001; 16: 134-138.
9. Norda R, Stegmayr BG: Therapeutic apher-esis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci 2003; 29: 159-166.
10. Rock G, Clark B, Sutton D: The Canadian Apheresis Registry. Transfus Apher Sci 2003; 29: 167-177.
11. Stegmayr B, Ptak J, Wikstrom B, et al: World Apheresis Registry 2003-2007 data. Trans-fus Apher Sci 2008; 39: 247-254.
12. Pusey C, Dash C, Garrett M, et al: Experience of using human albumin solution 4.5% in 1195 therapeutic plasma exchange procedures. Transfus Med 2010; 20:244-249.
13. Pusey CD: Anti-glomerular basement membrane disease. Kidney Int 2003; 64:1535-1550.
14. Johnson JP, Whitman W, Briggs WA, Wilson CB: Plasmapheresis and immunosuppressive agents in antibasement membrane antibody-induced Goodpasture's syndrome. Am J Med 1978; 64:354-359.
15. Levy JB, Turner AN, Rees AJ, Pusey CD: Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosup-pression. Ann Intern Med 2001; 134: 1033-1042.
16. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM: Plasma exchange in focal necrotizing glomerulonephritis without an-ti-GBM antibodies. Kidney Int 1991; 40: 757-763.
17. Szpirt WM, Heaf JG, Petersen J: Plasma exchange for induction and cyclosporine A for maintenance of remission in Wegener's granulomatosis-a clinical randomized controlled trial. Nephrol Dial Transplant 2011; 26: 206-213.
18. Walsh M, Catapano F, Szpirt W, et al: Plasma exchange for renal vasculitis and idiopathic rapidly progressive glomerulonephritis: a meta-analysis. Am J Kidney Dis 2011; 57: 566-574.
19. Klemmer PJ, Chalermskulrat W, Reif MS, Hogan SL, Henke DC, Falk RJ: Plasmapher-esis therapy for diffuse alveolar hemorrhage in patients with sma ll-vessel vasculitis. Am J Kidney Dis 2003; 42:1149-1153.
20. Deegens JK, Andresdottir MB, Croockewit S, Wetzels JF: Plasma exchange improves graft survival in patients with recurrent focal glomerulosclerosis after renal transplant. Transpl Int 2004; 17:151-157.
21. Gonzalez E, Ettenger R, Rianthavorn P, Tsai E, Malekzadeh M: Preemptive plasmapher-esis and recurrence of focal segmental glo-merulosclerosis in pediatric renal transplantation. Pediatr Transplant 2011; 15: 495-501.
22. Feld SM, Figueroa P, Savin V, et al: Plasma-pheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis 1998; 32: 230-237.
23. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM: A controlled trial of plasmapher-esis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992; 326:1373-1379.
24. Danieli MG, Palmieri C, Salvi A, Refe MC, Strusi AS, Danieli G: Synchronised therapy and high-dose cyclophosphamide in prolif-erative lupus nephritis. J Clin Apher 2002; 17: 72-77.
25. Frankel AH, Singer DR, Winearls CG, Evans DJ, Rees AJ, Pusey CD: Type II essential mixed cryoglobulinaemia: presentation, treatment and outcome in 13 patients. Q J Med 1992; 82: 101-124.
26. Berkman EM, Orlin JB: Use of plasmapher-esis and partial plasma exchange in the management of patients with cryoglobulinemia. Transfusion 1980; 20:171-178.
27. Clark WF, Stewart AK, Rock GA, et al: Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005; 143: 777-784.
28. Leung N, Gertz MA, Zeldenrust SR, et al: Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains. Kidney Int 2008; 73: 1282-1288.
29. Hutchison CA, Bradwell AR, Cook M, et al: Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off hemodialysis. Clin J Am Soc Nephrol 2009; 4:745-754.
30. Rizzoni G, Claris-Appiani A, Edefonti A, et al: Plasma infusion for hemolytic-uremic syndrome in children: results of a multi-center controlled trial. J Pediatr 1988; 112: 284-290.
31. Colic E, Dieperink H, Titlestad K, Tepel M: Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. La ncet 2011; 378: 1089-1093.
32. Rock GA, Shumak KH, Buskard NA, et al: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325:393-397.
33. Michael M, Elliott EJ, Ridley GF, Hodson EM, Craig JC: Interventions for haemolytic uraemic syndrome and thrombotic throm-bocytopenic purpura. Cochrane Database Syst Rev 2009:CD003595.
34. Tobian AA, Shirey RS, Montgomery RA, et al: ABO antibody titer and risk of antibody-mediated rejection in ABO-incompatible renal transplantation. Am J Transplant 2010; 10:1247-1253.
35. Snanoudj R, Candon S, Legendre C: Targeting B cells in sensitized kidney transplant patients: state of the art and future perspectives. Curr Opin Organ Transplant 2010, E-pub ahead of print.
36. White NB, Greenstein SM, Cantafio AW, et al: Successful rescue therapy with plasma-pheresis and intravenous immunoglobulin for acute humoral renal transplant rejection. Transplantation 2004; 78:772-774.
37. Rocha PN, Butterly DW, Greenberg A, et al: Benef ici a l ef fe ct of pla smaphere sis and i nt ravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003; 75: 149 0-149 5.
38. Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S: A comparison of plasmapheresis versus high-dose IVIG desensitization in re-na l a l log ra f t recipient s w it h h igh le vels of donor specific alloantibody. Am J Transplant 2006; 6: 346-351.
39. Higgins RM, Bevan DJ, Carey BS, et al: Prevention of hyperacute rejection by removal of antibodies to HLA immediately before renal transplantation. Lancet 1996; 348:1208-1211.
40. Salama AD, Delikouras A, Pusey CD, et al: Transplant accommodation in highly sensitized patients: a potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260-269.
41. Winters JL, Gloor JM, Pineda AA, Stegall MD, Moore SB: Plasma exchange conditioning for ABO-incompatible renal transplantation. J Clin Apher 2004; 19: 79-85.
42. Sonnenday CJ, Warren DS, Cooper M, et al: Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004; 4:1315-1322.